Vaxzevria info from European Medicines Agency

This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which co...  moreVaxzevria info from European Medicines Agency

This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by recombinant
DNA technology.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
 

How comes the org don't give the full details..

Vaxzevria info from European Medicines Agency

This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMP...  moreHow comes the org don't give the full details..

Vaxzevria info from European Medicines Agency

This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by recombinant
DNA technology.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
 

How comes the org don't give the full details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPO...  moreHow comes the org don't give the full details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by recombinant
DNA technology.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
 

How comes the org don't give these details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSIT...  moreHow comes the org don't give these details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by recombinant
DNA technology.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
 

How comes the org don't give these details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
NEW SAFETY INFORMATION. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSIT...  moreHow comes the org don't give these details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
NEW SAFETY INFORMATION. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by recombinant
DNA technology.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
 

How comes the org don't give these details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
NEW SAFETY INFORMATION. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSIT...  moreHow comes the org don't give these details..

Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
NEW SAFETY INFORMATION. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by RECOMBINANT
DNA TECHNOLOGY.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.